ALVO
NASDAQ · Biotechnology
Alvotech Sa
$3.72
+0.02 (+0.54%)
Open$3.70
Previous Close$3.70
Day High$3.73
Day Low$3.66
52W High$9.94
52W Low$2.94
Volume—
Avg Volume1.45M
Market Cap1.31B
P/E Ratio—
EPS$-0.28
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+752.7% upside
Current
$3.72
$3.72
Target
$31.72
$31.72
$22.31
$31.72 avg
$46.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 680.55M | 357.02M | 133.98M |
| Net Income | 32.28M | 15.24M | 26.13M |
| Profit Margin | 4.7% | 4.5% | 19.5% |
| EBITDA | 138.41M | 68.98M | 43.53M |
| Free Cash Flow | — | — | 33.36M |
| Rev Growth | +90.6% | +90.6% | +20.0% |
| Debt/Equity | — | — | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.93 | +0.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $352.99 | +1.72% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.88 | +0.66% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $478.81 | +2.22% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $626.31 | +1.34% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $300.33 | +4.22% | 64.3 | 37.13B |